Amgen Inc.
AMGNAmgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
Drugs in Pipeline
228
Phase 3 Programs
134
Upcoming Catalysts
13
Next Catalyst
This month
Market Overview
Stock performance and key metrics
13 upcoming, 4 past
Dazodalibep Phase 3 Est. Readout
Primary completion for Dazodalibep trial (NCT06245408) in Sjögren's Syndrome (SS)
Source12 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How AMGN's past catalysts played out
Lumakras
Sotorasib
KRAS G12C NSCLC
Vincrisitne
Leukemia, Acute Lymphoblastic
Lanadelumab
COVID-19
Topical Therapy
Plaque Psoriasis
ABP 938 8 mg
Neovascular Age-related Macular Degeneration
Lenalidomide
Relapsed Multiple Myeloma
FOLFOX regimen
Metastatic Colorectal Cancer
RP103
Cystinosis
Blinatumomab
Acute Lymphoblastic Leukemia
Adalimumab
Plaque Psoriasis
AMG 073
Secondary Hyperparathyroidism
Aranesp®
Kidney Disease
rHuEPO
Cancer
Apremilast 20mg
Psoriatic Arthritis
Evolocumab AMD
Primary Hypercholesterolemia
MP-376 (Levofloxacin Solution for Inhalation)
Cystic Fibrosis
De Novo Administration of Darbepoetin Alfa
Chronic Kidney Disease
Risendronate
Steroid-induced Osteopor, Glucocorticoid-induced Ostepor
Apremilast 30mg
Psoriatic Arthritis
Epoetin alfa RB
Nephrology
Actonel®
Osteoporosis
darbepoetin alfa
Anemia
Background Statin Therapy
Dyslipidemia
ABP 938
Neovascular (Wet) Age-related Macular Degeneration (AMD)
ARM 2
Recurrent and/or Metastatic Head and Neck Cancer
Cystagon®
Cystinosis
60 mg denosumab
Low Bone Mass
Zoledronic Acid
Bone Metastases
Denosumab
Osteoporosis
Best Supportive Care
Multiple Myeloma
Chemotherapy
Gastric Cancer
mFOLFOX6
Gastric Cancer
Aflibercept
Chorioretinal Vascular Disease
Oxaliplatin Based Chemotherapy
Colorectal Cancer
romosozumab HCP administration with PFS
Post-Menopausal Osteoporosis
Romosozumab 90 mg/mL
Postmenopausal Osteoporosis
Prednisone
ANCA-Associated Vasculitis
Recombinant Human Keratinocyte Growth Factor
Stomatitis
Denosumab (CP2)
Postmenopausal Osteoporosis
Topical treatments or phototherapy
Plaque Psoriasis
Standard Chemotherapy
Cancer
Anakinra (Kineret®)
Rheumatoid Arthritis
etanercept pre-filled syringe subcutaneous injection
Rheumatoid Arthritis
Apremilast 30 mg
Psoriatic Arthritis
Atorvastatin
Diabetes, Hyperlipidemia, Mixed Dyslipidemia
FOLFIRI
Metastatic Colorectal Cancer
Teprotumumab
Thyroid Eye Disease
1=Etanercept
Psoriasis
Statin therapy
Coronary Artery Disease (CAD)
Non-steroidal aromatase inhibitor therapy
Breast Cancer
pegfilgrastim
Breast Cancer
Pegloticase
Uncontrolled Gout
Inebilizumab
IgG4 Related Disease
Ibuprofen/famotidine
Ulcer
Denosumab (AMG 162)
Postmenopausal Osteoporosis
interferon γ-1b
Friedreich's Ataxia
ABP 234
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Ocrelizumab (US)
Relapsing-remitting Multiple Sclerosis (RRMS)
ABP 501
Arthritis, Rheumatoid
Ibandronate
Postmenopausal Osteoporosis
ABP 710
Arthritis, Rheumatoid
Sotorasib
Non-small Cell Lung Cancer
Aranesp® (darbepoetin alfa)
Kidney Disease
AMG 510
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Olpasiran
Cardiovascular Disease
Xaluritamig
Metastatic Castration-resistant Prostate Cancer
AMG 386
Ovarian Cancer
Pembrolizumab
Melanoma
Ezetimibe
Hyperlipidemia
Romiplostim
Chemotherapy-induced Thrombocytopenia
Erenumab Dose 1
Migraine
Etanercept / Autoinjector A
Rheumatoid Arthritis
ABP 654
Plaque Psoriasis
Erenumab Dose 2
Migraine
Denosumab (for the open-label treatment phase)
Cancer
AMG 531
Thrombocytopenia
AMG 162 / Denosumab
Breast Cancer
Dazodalibep
Sjögren's Syndrome (SS)
Topical agents
Psoriasis
Darbepoetin alfa - 2.25 mcg/kg
Anemia
AMG 162
Postmenopausal Osteoporosis
Cinacalcet HCl
Kidney Disease
Bemarituzumab
Gastric Cancer
HPN-100
Cirrhosis
Etanercept
Rheumatoid Arthritis
Cetuximab
Metastatic Colorectal Cancer
Dexamethasone
Relapsed and Refractory Multiple Myeloma
Low-intensity chemotherapy regimen
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Palifermin
Head and Neck Cancer
alendronate
Osteoporosis
Erenumab
Migraine
Cysteamine Bitartrate Delayed-release Capsules
Cystinosis
Maridebart cafraglutide
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Etoposide
Small-cell Lung Cancer
Aeroquin
Cystic Fibrosis
Commercial Formulation Etanercept
Arthritis, Rheumatoid; Arthritis, Psoriatic
ABP 959
Paroxysmal Nocturnal Hemoglobinuria
Apremilast
Behçet's Disease
Etelcalcetide
Secondary Hyperparathyroidism
ABP 206
Melanoma
Panitumumab
Metastatic Colorectal Cancer
Daratumumab
Relapsed Multiple Myeloma
Tarlatamab
Small Cell Lung Cancer
Cinacalcet
End Stage Renal Disease
Methotrexate
Psoriatic Arthritis
Cystagon® (Cysteamine Bitartrate)
Cystinosis
Evolocumab Pre-filled Syringe
Primary Hypercholesterolemia
Carfilzomib
Multiple Myeloma
Romozosumab
Postmenopausal Osteoporosis
Evolocumab
Hyperlipidemia
Ibuprofen
Peptic Ulcer
Darbepoetin alfa and Epoetin alfa
Anemia
Apremilast tablet 20 mg
Ankylosing Spondyloarthritis
Paclitaxel
Locally Recurrent and Metastatic Breast Cancer
darbepoetin alfa SF
Kidney Disease
Buphenyl (NaPBA)
Urea Cycle Disorders
FOLFIRI Regimen
Metastatic Colorectal Cancer
Etanercept Liquid
Rheumatoid Arthritis
MR prednisone
Rheumatoid Arthritis
HZT-501
Osteoarthritis
50 mg Etanercept
Rheumatoid Arthritis
Avacopan
Vasculitis
Lurbinectedin
Small Cell Lung Cancer (SCLC)
Epoetin alfa DT
Chronic Kidney Disease
ABP 798
Arthritis, Rheumatoid
Bortezomib
Multiple Myeloma
Romosozumab
Postmenopausal Women With Osteoporosis
ABP 980
Breast Cancer
Ustekinumab
Psoriasis
Abiraterone
Metastatic Castration-resistant Prostate Cancer
Rosuvastatin
Hyperlipidemia
Trifluridine and Tipiracil
Colorectal Cancer (CRC)
Apremilast (CC-10004)
Behcet Syndrome
Rocatinlimab
Asthma
Carboplatin
Non-small Cell Lung Cancer Metastatic
AMG 102
Cancer
CC10004
Psoriasis
Adecatumumab
Liver Metastases
AMG 531 (Romiplostim)
MDS
IV Bisphosphonates
Breast Cancer
Darbepoetin alfa SC
Anemia
pegfilgrastim 12 mg
Lymphoma
Sunitinib
Advanced Renal Cell Carcinoma
5-Fluorouracil
Colorectal Cancer
Panitumumab (ABX-EGF)
Advanced Renal Cell Carcinoma
AMG 853
Asthma
epratuzumab
Non-Hodgkin's Lymphoma
cinacalcet (AMG 073)
Secondary Hyperparathyroidism
Antizol
Aldehyde Dehydrogenase-2 (ALDH2) Deficiency
VIB7734
Lupus Erythematosus, Systemic
Modified FOLFOX6
Advanced Solid Tumors
AMG 827
Asthma
IV Bisphosphonate q 4 weeks
Bone Metastases in Men With Hormone-Refractory Prostate Cancer
Pegsunercept (PEG sTNF-RI)
Rheumatoid Arthritis
MP-376
Cystic Fibrosis (CF)
Teriparatide
Low Bone Mineral Density
CCX140-B
Diabetic Nephropathy
doxorubicin
Breast Cancer
AMG 102 at 10 mg/kg
Advanced Renal Cell Carcinoma
AMG 655
Metastatic Colorectal Cancer
BUPHENYL®
Urea Cycle Disorders
CCX-354-C
Rheumatoid Arthritis
100 mg AMG 162
Osteoporosis
filgrastim
Sarcoma
ABX-EGF
Non-small Cell Lung Cancer
VIB4920
Sjögren's Syndrome
Belatacept
Allografts
Conatumumab
Colon Cancer
cyclophosphamide
Breast Cancer
AMG 714
Psoriasis
AMG 719
Rheumatoid Arthritis
AMG 732
Thyroid Eye Disease
Abrilumab
Ulcerative Colitis
Brodalumab
Rheumatoid Arthritis
Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
Anemia
Tezepelumab Dose 1
Chronic Spontaneous Urticaria
Cysteamine Bitartrate
Inherited Mitochondrial Disease, Including Leigh Syndrome
Recombinant Human Erythropoietin
Breast Cancer
Irinotecan
Metastatic Colorectal Cancer
CCX168
Vasculitis
ABX-EGF (panitumumab)
Metastatic Colorectal Cancer
IDE397
MTAP-null Non-Small-Cell Lung Cancer
recombinant human erythropoietin (rHuEPO)
Gynecological Malignancies
AMG 951 (rhApo2L/TRAIL)
Non-Small Cell Lung Cancer
HZN-1116
Sjogren's Syndrome
Gemcitabine
Lung Cancer
Investigator's Choice Chemotherapy
High-risk Diffuse Large B-Cell Lymphoma
Cisplatin
Squamous Cell Carcinoma of Head and Neck
pioglitazone
Type 2 Diabetes Mellitus
Talimogene laherparepvec
Melanoma
AMG 193
MTAP-deleted NSCLC
Systemic AMG 108
Osteoarthritis
Blinatumomab (MT103)
Acute Lymphoblastic Leukemia
anakinra
Rheumatoid Arthritis
Capecitabine
Esophagogastric Junction Adenocarcinoma
AMG 317 75 mg
Asthma
Liatermin
Parkinson's Disease
Daxdilimab
Alopecia Areata
AMG 151
Diabetes Mellitus
Intra-articular metHuIL-1ra (anakinra)
Osteoarthritis
Docetaxel
Advanced MTAP-null Solid Tumors
IV iron dextran
Anemia
Pemetrexed
Non Small Cell Lung Cancer
Neulasta
Breast Cancer
CC-11050
Cutaneous Lupus Erythematosus
Erenumab PFS
Migraine
AMG 102 at 20 mg/kg
Advanced Malignant Glioma
CCX 354-C
Rheumatoid Arthritis
AMG 706
Gastrointestinal Cancer
AMG 337
Stomach Neoplasms
Apremilast 10mg
Psoriasis
AMG 386 10mg/kg
Gastrointestinal Cancer
Pomalidomide
Relapsed or Refractory Multiple Myeloma
Naproxen
Bone Pain in Stage I - III Breast Cancer
CC-10004
Psoriasis
Oprozomib
Multiple Myeloma
Previous denosumab
Low Bone Mass
Sensipar (Cinacalcet HCl)
Secondary Hyperparathyroidism
AMG 301
Chronic Migraine or Episodic Migraine
AMG 108
Rheumatoid Arthritis
Sorafenib
Advanced Hepatocellular Carcinoma
Lodotra
Asthma
CCX282-B
Crohn's Disease
AMG 223
End Stage Renal Disease
NaPBA
Urea Cycle Disorders
Motesanib diphosphate
Lung Cancer
Rozibafusp Alfa
Systemic Lupus Erythematosus (SLE)
AMG 509
Prostate Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Lumakras Sotorasib | Approved | KRAS G12C NSCLC | Fast TrackBreakthrough | Patent 2040 |
Vincrisitne | Phase 3 | Leukemia, Acute Lymphoblastic | - | - |
Lanadelumab | Phase 3 | COVID-19 | - | - |
Topical Therapy | Phase 3 | Plaque Psoriasis | - | - |
ABP 938 8 mg | Phase 3 | Neovascular Age-related Macular Degeneration | - | - |
Lenalidomide | Phase 3 | Relapsed Multiple Myeloma | - | - |
FOLFOX regimen | Phase 3 | Metastatic Colorectal Cancer | - | - |
RP103 | Phase 3 | Cystinosis | - | - |
Blinatumomab | Phase 3 | Acute Lymphoblastic Leukemia | - | - |
Adalimumab | Phase 3 | Plaque Psoriasis | - | - |
AMG 073 | Phase 3 | Secondary Hyperparathyroidism | - | - |
Aranesp® | Phase 3 | Kidney Disease | - | - |
rHuEPO | Phase 3 | Cancer | - | - |
Apremilast 20mg | Phase 3 | Psoriatic Arthritis | - | - |
Evolocumab AMD | Phase 3 | Primary Hypercholesterolemia | - | - |
MP-376 (Levofloxacin Solution for Inhalation) | Phase 3 | Cystic Fibrosis | - | - |
De Novo Administration of Darbepoetin Alfa | Phase 3 | Chronic Kidney Disease | - | - |
Risendronate | Phase 3 | Steroid-induced Osteopor, Glucocorticoid-induced Ostepor | - | - |
Apremilast 30mg | Phase 3 | Psoriatic Arthritis | - | - |
Epoetin alfa RB | Phase 3 | Nephrology | - | - |
Actonel® | Phase 3 | Osteoporosis | - | - |
darbepoetin alfa | Phase 3 | Anemia | - | - |
Background Statin Therapy | Phase 3 | Dyslipidemia | - | - |
ABP 938 | Phase 3 | Neovascular (Wet) Age-related Macular Degeneration (AMD) | - | - |
ARM 2 | Phase 3 | Recurrent and/or Metastatic Head and Neck Cancer | - | - |
Cystagon® | Phase 3 | Cystinosis | - | - |
60 mg denosumab | Phase 3 | Low Bone Mass | - | - |
Zoledronic Acid | Phase 3 | Bone Metastases | - | - |
Denosumab | Phase 3 | Osteoporosis | - | - |
Best Supportive Care | Phase 3 | Multiple Myeloma | - | - |
Chemotherapy | Phase 3 | Gastric Cancer | - | - |
mFOLFOX6 | Phase 3 | Gastric Cancer | - | - |
Aflibercept | Phase 3 | Chorioretinal Vascular Disease | - | - |
Oxaliplatin Based Chemotherapy | Phase 3 | Colorectal Cancer | - | - |
romosozumab HCP administration with PFS | Phase 3 | Post-Menopausal Osteoporosis | - | - |
Romosozumab 90 mg/mL | Phase 3 | Postmenopausal Osteoporosis | - | - |
Prednisone | Phase 3 | ANCA-Associated Vasculitis | - | - |
Recombinant Human Keratinocyte Growth Factor | Phase 3 | Stomatitis | - | - |
Denosumab (CP2) | Phase 3 | Postmenopausal Osteoporosis | - | - |
Topical treatments or phototherapy | Phase 3 | Plaque Psoriasis | - | - |
Standard Chemotherapy | Phase 3 | Cancer | - | - |
Anakinra (Kineret®) | Phase 3 | Rheumatoid Arthritis | - | - |
etanercept pre-filled syringe subcutaneous injection | Phase 3 | Rheumatoid Arthritis | - | - |
Apremilast 30 mg | Phase 3 | Psoriatic Arthritis | - | - |
Atorvastatin | Phase 3 | Diabetes, Hyperlipidemia, Mixed Dyslipidemia | - | - |
FOLFIRI | Phase 3 | Metastatic Colorectal Cancer | - | - |
Teprotumumab | Phase 3 | Thyroid Eye Disease | - | - |
1=Etanercept | Phase 3 | Psoriasis | - | - |
Statin therapy | Phase 3 | Coronary Artery Disease (CAD) | - | - |
Non-steroidal aromatase inhibitor therapy | Phase 3 | Breast Cancer | - | - |
pegfilgrastim | Phase 3 | Breast Cancer | - | - |
Pegloticase | Phase 3 | Uncontrolled Gout | - | - |
Inebilizumab | Phase 3 | IgG4 Related Disease | - | - |
Ibuprofen/famotidine | Phase 3 | Ulcer | - | - |
Denosumab (AMG 162) | Phase 3 | Postmenopausal Osteoporosis | - | - |
interferon γ-1b | Phase 3 | Friedreich's Ataxia | - | - |
ABP 234 | Phase 3 | Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | - | - |
Ocrelizumab (US) | Phase 3 | Relapsing-remitting Multiple Sclerosis (RRMS) | - | - |
ABP 501 | Phase 3 | Arthritis, Rheumatoid | - | - |
Ibandronate | Phase 3 | Postmenopausal Osteoporosis | - | - |
ABP 710 | Phase 3 | Arthritis, Rheumatoid | - | - |
Sotorasib | Phase 3 | Non-small Cell Lung Cancer | - | - |
Aranesp® (darbepoetin alfa) | Phase 3 | Kidney Disease | - | - |
AMG 510 | Phase 3 | KRAS p, G12c Mutated /Advanced Metastatic NSCLC | - | - |
Olpasiran | Phase 3 | Cardiovascular Disease | - | - |
Xaluritamig | Phase 3 | Metastatic Castration-resistant Prostate Cancer | - | - |
AMG 386 | Phase 3 | Ovarian Cancer | - | - |
Pembrolizumab | Phase 3 | Melanoma | - | - |
Ezetimibe | Phase 3 | Hyperlipidemia | - | - |
Romiplostim | Phase 3 | Chemotherapy-induced Thrombocytopenia | - | - |
Erenumab Dose 1 | Phase 3 | Migraine | - | - |
Etanercept / Autoinjector A | Phase 3 | Rheumatoid Arthritis | - | - |
ABP 654 | Phase 3 | Plaque Psoriasis | - | - |
Erenumab Dose 2 | Phase 3 | Migraine | - | - |
Denosumab (for the open-label treatment phase) | Phase 3 | Cancer | - | - |
AMG 531 | Phase 3 | Thrombocytopenia | - | - |
AMG 162 / Denosumab | Phase 3 | Breast Cancer | - | - |
Dazodalibep | Phase 3 | Sjögren's Syndrome (SS) | - | - |
Topical agents | Phase 3 | Psoriasis | - | - |
Darbepoetin alfa - 2.25 mcg/kg | Phase 3 | Anemia | - | - |
AMG 162 | Phase 3 | Postmenopausal Osteoporosis | - | - |
Cinacalcet HCl | Phase 3 | Kidney Disease | - | - |
Bemarituzumab | Phase 3 | Gastric Cancer | - | - |
HPN-100 | Phase 3 | Cirrhosis | - | - |
Etanercept | Phase 3 | Rheumatoid Arthritis | - | - |
Cetuximab | Phase 3 | Metastatic Colorectal Cancer | - | - |
Dexamethasone | Phase 3 | Relapsed and Refractory Multiple Myeloma | - | - |
Low-intensity chemotherapy regimen | Phase 3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | - | - |
Palifermin | Phase 3 | Head and Neck Cancer | - | - |
alendronate | Phase 3 | Osteoporosis | - | - |
Erenumab | Phase 3 | Migraine | - | - |
Cysteamine Bitartrate Delayed-release Capsules | Phase 3 | Cystinosis | - | - |
Maridebart cafraglutide | Phase 3 | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | - | - |
Etoposide | Phase 3 | Small-cell Lung Cancer | - | - |
Aeroquin | Phase 3 | Cystic Fibrosis | - | - |
Commercial Formulation Etanercept | Phase 3 | Arthritis, Rheumatoid; Arthritis, Psoriatic | - | - |
ABP 959 | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
Apremilast | Phase 3 | Behçet's Disease | - | - |
Etelcalcetide | Phase 3 | Secondary Hyperparathyroidism | - | - |
ABP 206 | Phase 3 | Melanoma | - | - |
Panitumumab | Phase 3 | Metastatic Colorectal Cancer | - | - |
Daratumumab | Phase 3 | Relapsed Multiple Myeloma | - | - |
Tarlatamab | Phase 3 | Small Cell Lung Cancer | OrphanFast TrackBreakthrough | |
Cinacalcet | Phase 3 | End Stage Renal Disease | - | - |
Methotrexate | Phase 3 | Psoriatic Arthritis | - | - |
Cystagon® (Cysteamine Bitartrate) | Phase 3 | Cystinosis | - | - |
Evolocumab Pre-filled Syringe | Phase 3 | Primary Hypercholesterolemia | - | - |
Carfilzomib | Phase 3 | Multiple Myeloma | - | - |
Romozosumab | Phase 3 | Postmenopausal Osteoporosis | - | - |
Evolocumab | Phase 3 | Hyperlipidemia | - | - |
Ibuprofen | Phase 3 | Peptic Ulcer | - | - |
Darbepoetin alfa and Epoetin alfa | Phase 3 | Anemia | - | - |
Apremilast tablet 20 mg | Phase 3 | Ankylosing Spondyloarthritis | - | - |
Paclitaxel | Phase 3 | Locally Recurrent and Metastatic Breast Cancer | - | - |
darbepoetin alfa SF | Phase 3 | Kidney Disease | - | - |
Buphenyl (NaPBA) | Phase 3 | Urea Cycle Disorders | - | - |
FOLFIRI Regimen | Phase 3 | Metastatic Colorectal Cancer | - | - |
Etanercept Liquid | Phase 3 | Rheumatoid Arthritis | - | - |
MR prednisone | Phase 3 | Rheumatoid Arthritis | - | - |
HZT-501 | Phase 3 | Osteoarthritis | - | - |
50 mg Etanercept | Phase 3 | Rheumatoid Arthritis | - | - |
Avacopan | Phase 3 | Vasculitis | - | - |
Lurbinectedin | Phase 3 | Small Cell Lung Cancer (SCLC) | - | - |
Epoetin alfa DT | Phase 3 | Chronic Kidney Disease | - | - |
ABP 798 | Phase 3 | Arthritis, Rheumatoid | - | - |
Bortezomib | Phase 3 | Multiple Myeloma | - | - |
Romosozumab | Phase 3 | Postmenopausal Women With Osteoporosis | - | - |
ABP 980 | Phase 3 | Breast Cancer | - | - |
Ustekinumab | Phase 3 | Psoriasis | - | - |
Abiraterone | Phase 3 | Metastatic Castration-resistant Prostate Cancer | - | - |
Rosuvastatin | Phase 3 | Hyperlipidemia | - | - |
Trifluridine and Tipiracil | Phase 3 | Colorectal Cancer (CRC) | - | - |
Apremilast (CC-10004) | Phase 3 | Behcet Syndrome | - | - |
Rocatinlimab | Phase 3 | Asthma | - | - |
Carboplatin | Phase 3 | Non-small Cell Lung Cancer Metastatic | - | - |
AMG 102 | Phase 2 | Cancer | - | - |
CC10004 | Phase 2 | Psoriasis | - | - |
Adecatumumab | Phase 2 | Liver Metastases | - | - |
AMG 531 (Romiplostim) | Phase 2 | MDS | - | - |
IV Bisphosphonates | Phase 2 | Breast Cancer | - | - |
Darbepoetin alfa SC | Phase 2 | Anemia | - | - |
pegfilgrastim 12 mg | Phase 2 | Lymphoma | - | - |
Sunitinib | Phase 2 | Advanced Renal Cell Carcinoma | - | - |
5-Fluorouracil | Phase 2 | Colorectal Cancer | - | - |
Panitumumab (ABX-EGF) | Phase 2 | Advanced Renal Cell Carcinoma | - | - |
AMG 853 | Phase 2 | Asthma | - | - |
epratuzumab | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
cinacalcet (AMG 073) | Phase 2 | Secondary Hyperparathyroidism | - | - |
Antizol | Phase 2 | Aldehyde Dehydrogenase-2 (ALDH2) Deficiency | - | - |
VIB7734 | Phase 2 | Lupus Erythematosus, Systemic | - | - |
Modified FOLFOX6 | Phase 2 | Advanced Solid Tumors | - | - |
AMG 827 | Phase 2 | Asthma | - | - |
IV Bisphosphonate q 4 weeks | Phase 2 | Bone Metastases in Men With Hormone-Refractory Prostate Cancer | - | - |
Pegsunercept (PEG sTNF-RI) | Phase 2 | Rheumatoid Arthritis | - | - |
MP-376 | Phase 2 | Cystic Fibrosis (CF) | - | - |
Teriparatide | Phase 2 | Low Bone Mineral Density | - | - |
CCX140-B | Phase 2 | Diabetic Nephropathy | - | - |
doxorubicin | Phase 2 | Breast Cancer | - | - |
AMG 102 at 10 mg/kg | Phase 2 | Advanced Renal Cell Carcinoma | - | - |
AMG 655 | Phase 2 | Metastatic Colorectal Cancer | - | - |
BUPHENYL® | Phase 2 | Urea Cycle Disorders | - | - |
CCX-354-C | Phase 2 | Rheumatoid Arthritis | - | - |
100 mg AMG 162 | Phase 2 | Osteoporosis | - | - |
filgrastim | Phase 2 | Sarcoma | - | - |
ABX-EGF | Phase 2 | Non-small Cell Lung Cancer | - | - |
VIB4920 | Phase 2 | Sjögren's Syndrome | - | - |
Belatacept | Phase 2 | Allografts | - | - |
Conatumumab | Phase 2 | Colon Cancer | - | - |
cyclophosphamide | Phase 2 | Breast Cancer | - | - |
AMG 714 | Phase 2 | Psoriasis | - | - |
AMG 719 | Phase 2 | Rheumatoid Arthritis | - | - |
AMG 732 | Phase 2 | Thyroid Eye Disease | - | - |
Abrilumab | Phase 2 | Ulcerative Colitis | - | - |
Brodalumab | Phase 2 | Rheumatoid Arthritis | - | - |
Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa) | Phase 2 | Anemia | - | - |
Tezepelumab Dose 1 | Phase 2 | Chronic Spontaneous Urticaria | - | - |
Cysteamine Bitartrate | Phase 2 | Inherited Mitochondrial Disease, Including Leigh Syndrome | - | - |
Recombinant Human Erythropoietin | Phase 2 | Breast Cancer | - | - |
Irinotecan | Phase 2 | Metastatic Colorectal Cancer | - | - |
CCX168 | Phase 2 | Vasculitis | - | - |
ABX-EGF (panitumumab) | Phase 2 | Metastatic Colorectal Cancer | - | - |
IDE397 | Phase 2 | MTAP-null Non-Small-Cell Lung Cancer | - | - |
recombinant human erythropoietin (rHuEPO) | Phase 2 | Gynecological Malignancies | - | - |
AMG 951 (rhApo2L/TRAIL) | Phase 2 | Non-Small Cell Lung Cancer | - | - |
HZN-1116 | Phase 2 | Sjogren's Syndrome | - | - |
Gemcitabine | Phase 2 | Lung Cancer | - | - |
Investigator's Choice Chemotherapy | Phase 2 | High-risk Diffuse Large B-Cell Lymphoma | - | - |
Cisplatin | Phase 2 | Squamous Cell Carcinoma of Head and Neck | - | - |
pioglitazone | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Talimogene laherparepvec | Phase 2 | Melanoma | - | - |
AMG 193 | Phase 2 | MTAP-deleted NSCLC | - | - |
Systemic AMG 108 | Phase 2 | Osteoarthritis | - | - |
Blinatumomab (MT103) | Phase 2 | Acute Lymphoblastic Leukemia | - | - |
anakinra | Phase 2 | Rheumatoid Arthritis | - | - |
Capecitabine | Phase 2 | Esophagogastric Junction Adenocarcinoma | - | - |
AMG 317 75 mg | Phase 2 | Asthma | - | - |
Liatermin | Phase 2 | Parkinson's Disease | - | - |
Daxdilimab | Phase 2 | Alopecia Areata | - | - |
AMG 151 | Phase 2 | Diabetes Mellitus | - | - |
Intra-articular metHuIL-1ra (anakinra) | Phase 2 | Osteoarthritis | - | - |
Docetaxel | Phase 2 | Advanced MTAP-null Solid Tumors | - | - |
IV iron dextran | Phase 2 | Anemia | - | - |
Pemetrexed | Phase 2 | Non Small Cell Lung Cancer | - | - |
Neulasta | Phase 2 | Breast Cancer | - | - |
CC-11050 | Phase 2 | Cutaneous Lupus Erythematosus | - | - |
Erenumab PFS | Phase 2 | Migraine | - | - |
AMG 102 at 20 mg/kg | Phase 2 | Advanced Malignant Glioma | - | - |
CCX 354-C | Phase 2 | Rheumatoid Arthritis | - | - |
AMG 706 | Phase 2 | Gastrointestinal Cancer | - | - |
AMG 337 | Phase 2 | Stomach Neoplasms | - | - |
Apremilast 10mg | Phase 2 | Psoriasis | - | - |
AMG 386 10mg/kg | Phase 2 | Gastrointestinal Cancer | - | - |
Pomalidomide | Phase 2 | Relapsed or Refractory Multiple Myeloma | - | - |
Naproxen | Phase 2 | Bone Pain in Stage I - III Breast Cancer | - | - |
CC-10004 | Phase 2 | Psoriasis | - | - |
Oprozomib | Phase 2 | Multiple Myeloma | - | - |
Previous denosumab | Phase 2 | Low Bone Mass | - | - |
Sensipar (Cinacalcet HCl) | Phase 2 | Secondary Hyperparathyroidism | - | - |
AMG 301 | Phase 2 | Chronic Migraine or Episodic Migraine | - | - |
AMG 108 | Phase 2 | Rheumatoid Arthritis | - | - |
Sorafenib | Phase 2 | Advanced Hepatocellular Carcinoma | - | - |
Lodotra | Phase 2 | Asthma | - | - |
CCX282-B | Phase 2 | Crohn's Disease | - | - |
AMG 223 | Phase 2 | End Stage Renal Disease | - | - |
NaPBA | Phase 2 | Urea Cycle Disorders | - | - |
Motesanib diphosphate | Phase 2 | Lung Cancer | - | - |
Rozibafusp Alfa | Phase 2 | Systemic Lupus Erythematosus (SLE) | - | - |
AMG 509 | Phase 1 | Prostate Cancer | Fast Track | - |
KRAS G12C NSCLC
1 drug in this indication
Small Cell Lung Cancer
1 drug in this indication
Prostate Cancer
1 drug in this indication
reduction of cardiovascular risk, prevention of first myocardial infarction or stroke
1 drug in this indication
Cardiovascular risk reduction, primary prevention of myocardial infarction and stroke
1 drug in this indication
Reduction of risk of first myocardial infarction or stroke in patients with cardiovascular disease
1 drug in this indication
primary prevention of myocardial infarction and stroke
1 drug in this indication
rare disease
1 drug in this indication
Reduction of risk of first myocardial infarction or stroke
1 drug in this indication
reduction of risk of first heart attack or stroke
1 drug in this indication
lung cancer
1 drug in this indication
Systemic Lupus Erythematosus (SLE)
1 drug in this indication
Rheumatoid Arthritis
1 drug in this indication
rare kidney disease
1 drug in this indication
ANCA-associated vasculitis (AAV)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Amgen Inc.'s drug pipeline?→
CatalystAlert tracks 228 drug candidates in Amgen Inc.'s (AMGN) pipeline across Phase 3, Phase 2, Phase 1, Approved. Its lead program is Vincrisitne (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Amgen Inc.'s next FDA catalyst?→
Amgen Inc.'s (AMGN) next tracked catalyst is a Phase 3 expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AMGN biotech catalysts?→
Add AMGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Amgen Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.